Introduction
============

Lung cancer is one of the most severe malignant tumors in humans,[@b1-ott-9-2683] while the adenocarcinoma, a leading aggressive histopathologic type of lung cancer, has become more and more prevalent recently.[@b2-ott-9-2683] With the improvement of imaging and screening techniques for high-risk individuals with adenocarcinomas,[@b3-ott-9-2683] especially those with diameter ≤2 cm, it has already been detected frequently. Unfortunately, because of the malignant features of early metastasis and recurrence, patients with lung adenocarcinoma even in early stage only have the 50%--70% 5-year survival rate.[@b4-ott-9-2683] Currently, the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society (IASLC/ATS/ERS)'s international multidisciplinary classification of lung adenocarcinoma has been widely introduced since 2011 relying on morphological characteristics and invasiveness.[@b5-ott-9-2683] However, different gene phenotypes existing in the individuals might lead to a significant difference in their outcomes.[@b6-ott-9-2683],[@b7-ott-9-2683] Therefore, it is necessary to detect and identify new molecular biomarkers in order to get a more accurate prediction of prognosis and recurrence in patients with lung adenocarcinoma.

YBX1, a member of the DNA-binding protein family with an evolutionary ancient cold-shock domain, was reported to participate in the transcriptional activation of genes, the promoters of which contain an inverted CCAAT box (Y-box sequence).[@b8-ott-9-2683]--[@b10-ott-9-2683] Upon the stimulation of outside stress, YBX1 shifted from cytoplasm to nucleus and bound to the promoter of the targeting genes, such as epidermal growth factor receptor,[@b11-ott-9-2683] multidrug resistance 1,[@b12-ott-9-2683] and cell division cycle 6[@b13-ott-9-2683] and, thereafter, regulated the transcription of these genes in a variety of tumor cells. Recent research has shown that the *YBX1* was involved in the tumor formation, proliferation, drug resistance, and prognosis as an oncogene.[@b14-ott-9-2683]--[@b16-ott-9-2683] Nevertheless, its expression and prognostic significances were scarcely reported in lung adenocarcinoma, especially in small (≤2 cm) invasive lung adenocarcinoma.

This study was presented to retrospectively evaluate the expression of YBX1 in patients with small invasive lung adenocarcinoma and analyze its impact on patients' prognosis and recurrence by using immunohistochemical (IHC) staining. The high *YBX1* expression was found in the small invasive lung adenocarcinoma and predicted the poor prognosis.

Materials and methods
=====================

Patients and follow-up
----------------------

A total of 75 consecutive patients (median age: 64 years; range from 45 years to 83 years) with small invasive lung adenocarcinoma who underwent radical surgery of the primary tumor and systematic nodal dissection at the First Affiliated Hospital of Dalian Medical University from January 2008 to December 2010, were enrolled. The inclusion criteria of the study were based on invasive lung adenocarcinomas of the lesions ≤2 cm in diameter identified by routine histopathologic examination. The patients who received chemotherapy or radiotherapy prior to the operation were excluded. The clinical data of the enrolled patients was obtained from our institution (Lung Cancer Diagnosis and Treatment Center). The tumor stage was classified according to the seventh revision of TNM (tumor, nodes, metastases) staging of the international system for lung cancer.[@b17-ott-9-2683]

For the postoperative follow-up, we followed our previous program.[@b18-ott-9-2683] Briefly, patients were followed every 3 months within the first year and at ∼6-month intervals thereafter. During the follow-up time, physical examination, chest radiography, analysis of blood chemistry, and carcinoembryonic antigen assay were performed. If any symptom or sign of recurrence appeared in these examinations, further evaluations to detect the recurrent site were carried out. The terminal follow-up time was January 2013 (median follow-up: 32 months). The study was approved by the Medical Ethical Committees of the First Affiliated Hospital of Dalian Medical University, all patients provided written informed consent and agreed their tissue samples could be used for clinical research but not commercial use.

Antibodies and other reagents
-----------------------------

The primary antibodies (ab12148) against YBX1 were purchased from Abcam (Cambridge, UK). The antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was obtained from Proteintech Group, Inc. (Chicago, IL, USA). The Biotin-Streptavidin HRP Detection Systems was ordered from ZSGB-BIO (Beijing, People's Republic of China), and all the other chemicals were purchased from Sigma Chemicals (Perth, Australia).

Histopathology evaluation
-------------------------

The formalin-fixed, paraffin-embedded, 3 μm section was obtained from 75 samples of primary lesions. All specimens were stained with hematoxylin and eosin for histopathologic diagnosis. Pathology assessment of each slide was independently examined by two pulmonary pathologists (Dr Li and Dr Gu) according to IASLC/ATS/ERS's international multidisciplinary classification of lung adenocarcinoma.[@b5-ott-9-2683] Further verification was performed by the senior pathologist (Dr Sun), if there was any dispute of diagnosis between them. The invasive lung adenocarcinoma included the following: lepidic, acinar, papillary, micropapillary, solid, and mucinous predominant adenocarcinoma.

Immunohistochemistry staining
-----------------------------

IHC staining of YBX1 was performed in primary lesions and normal adjacent tissues according to the manufacturer's instructions of the streptavidin--peroxidase staining kit. Briefly, the sections were dewaxed, rehydrated, treated with antigen retrieval solution, serum blocked, and then incubated with polyclonal YBX1 antibody (diluted to the ratio of 1:100 in phosphate buffered saline containing 2% bovine serum albumin) overnight at 4°C. The following day, 3,3′-diaminobenzidine (DAB) staining was performed and the result was assessed by two pathologists using a blind protocol design. Positive expression of YBX1 was indicated by pale brown cell cytoplasm, cytomembrane, and nucleus. The final overall assessed score of each specimen was calculated as intensity expression (negative, 0 points; weak, 1 points; moderate, 2 points; and strong, 3 points) multiplying with stained cell numbers (positive cells as ≤25% of the cells, 1 points; 26%--50% of the cells, 2 points; 51%--75% of the cells, 3 points; \>75% of the cells, 4 points).[@b19-ott-9-2683] Subsequently, the expression of YBX1 in primary lesions and normal adjacent structure was graded. To precisely assess the overall expression of YBX1 in primary lesions, receiver operating characteristic (ROC) curve analyses were carried out by two experienced pathologists based on the graded score of primary lesions and normal adjacent structure. As shown in [Figure 1](#f1-ott-9-2683){ref-type="fig"}, when the cutoff score of YBX1 expression was 3.5 points, the maximized sensitivity and specificity of YBX1 for distinguishing lung adenocarcinoma from normal human lung tissue was 66.7% and 74.7%, respectively (area under the ROC curve =0.731; *P*\<0.001). Therefore, YBX1 was considered to be highly expressed when the score was \>3.5, otherwise it was considered to be less expressed.

Cell lines and cell culture
---------------------------

Human lung adenocarcinoma cell lines (A549, H322, Hcc827, and H1299) and normal human embryonic lung fibroblasts HLF cell line were used in this study. The A549 cells were cultured in F12K medium/Dulbecco's Modified Eagle's Medium (1:1) (HyClone; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum, and the other cells were grown in RPMI 1640 medium with 10% fetal bovine serum. All cells were maintained at 37°C in a humidified atmosphere containing 5% CO~2~.

Western blot analysis
---------------------

Cells grown to subconfluence were separated by trypsin digestion and collected. Total proteins were extracted using mammalian protein extraction kit (KW-BIO, Beijing, People's Republic of China) and then quantified by BCA protein assay kit (Thermo Fisher Scientific). Western blot analyses were performed according to the protocols for the routine measurement of antibodies against YBX1 (diluted 1:2,000) and GAPDH (diluted 1:5,000), respectively. Protein bands were developed with enhanced chemiluminescence system.

Statistical analysis
--------------------

ROC curve analyses were performed to assess the cutoff levels of YBX1 expression, and the comparison of areas under the ROC curve was performed by *Z*-test. Statistical significance was evaluated using the chi-square test. Survival curves were plotted according to the Kaplan--Meier method, and differences between the curves were analyzed by the log-rank test. Cox proportional hazards model was applied to the multivariate survival analysis. Differences were considered to be statistically significant for *P*-values of \<0.05. Data were analyzed using SPSS 20 software (IBM Corporation, Armonk, NY, USA).

Results
=======

Clinicopathologic characteristics
---------------------------------

The basic clinicopathologic characteristics of 75 patients with small invasive lung adenocarcinoma are summarized in [Table 1](#t1-ott-9-2683){ref-type="table"}. Of 75 patients, 38 (50.7%) were female and 37 (49.3%) were were male; 58 (77.3%) patients with stage Ia, seven patients with TNM stage Ib, and ten with TNM stage IIa. Ten (13.3%) and eight (10.7%) patients showed lymph node metastasis and pleural invasion in postoperative pathology, respectively. Lobectomy was employed on 62 patients (87.2%), and the remaining 13 patients received partial resection. From the point of postoperative pathology, the number of patients with low, middle, and high risk of pathological grade was 22, 40, and 13, respectively, and the number of patients with lepidic, acinar, papillary, micropapillary, solid, and mucinous predominant adenocarcinoma among the individuals was 22, 29, 11, 5, 3, and 5, respectively. During the follow-up time, 20 (26.7%) of 75 patients encountered early recurrence (pulmonary metastasis, 12 cases; bone metastasis, two cases; lymphatic metastasis, 16 cases; and brain metastases one case), and 18 (24.0%) patients died due to primary disease.

Correlation between YBX1 expression and clinicopathologic factors
-----------------------------------------------------------------

The YBX1 IHC staining is usually seen in the cytoplasm or cell membranes and few appeared in cell nucleus (\<3%). Among the 75 specimens, high YBX1 expression was detected in 31 (41.3%) patients, and typical appearances of high and low YBX1 expression at different pathological grade risk are shown in [Figure 2](#f2-ott-9-2683){ref-type="fig"}. Furthermore, as shown in [Table 2](#t2-ott-9-2683){ref-type="table"}, YBX1 expression was found to be positively correlated with pathological grade (*P*=0.026) and differentiation (*P*=0.009) but not with sex, age, tumor size, TNM staging, pleural invasion, and lymph node metastasis. The patients with the higher risk grade or poorer differentiation tend to have more YBX1 expression.

High expression of YBX1 in human lung adenocarcinoma cell lines
---------------------------------------------------------------

We detected the expression of YBX1 in different lung adenocarcinoma cell lines (A549, H322, Hcc827, and H1299) and one normal human embryonic lung fibroblast (HLF cell line) by Western blot assay. The higher expression of YBX1 emerged in lung adenocarcinoma cell lines by comparison with HLF cells ([Figure 3](#f3-ott-9-2683){ref-type="fig"}).

Influence of risk factor on survival and recurrence
---------------------------------------------------

The influence of YBX1 expression and other clinical factors on the patients' overall survival (OS) was evaluated. As shown in [Figure 4](#f4-ott-9-2683){ref-type="fig"} and [Table 3](#t3-ott-9-2683){ref-type="table"}, the Kaplan--Meier survival curves of all 75 patients demonstrated that the patients with higher pathological grade risk (*P*=0.014), poorer differentiation (*P*=0.014), lymph node metastasis (*P*=0.037), elevated TNM staging (*P*=0.042), and high YBX1 expression (*P*=0.039) had a shorter OS. In contrast, patients with low YBX1 expression lived longer (5-year OS, 52.3%) than those with high expression (5-year OS, 79.0%). To our excitement, elevated TNM staging (odds ratio \[OR\] =3.323; 95% confidence interval \[CI\], 1.059--10.432; *P*=0.040) and high YBX1 expression (OR =2.737; 95% CI, 1.058--7.082; *P*=0.038) were shown as independent risk factors of OS in further multivariate analysis ([Table 4](#t4-ott-9-2683){ref-type="table"}). On the other hand, we found that pathological grade risk (*P*=0.035), differentiation (*P*\<0.001), pleural invasion (*P*=0.020), lymph node metastasis (*P*=0.036), TNM staging (*P*=0.044), and YBX1 expression (*P*=0.024) were related to the disease-free survival (DFS) in addition to the following: sex, age, surgical procedures, and tumor size ([Figure 5](#f5-ott-9-2683){ref-type="fig"}). However, it was a pity that high expression of YBX1 (OR =1.696; 95% CI: 0.616--4.673; *P*=0.307) was ruled out as a confounding factor by using Cox proportional hazards model, and only the differentiation was shown as an independent risk factor of 5-year DFS in further multivariate analysis ([Table 5](#t5-ott-9-2683){ref-type="table"}).

Discussion
==========

Adenocarcinoma is the main pathological type of non-small cell lung cancer and accounts for \>50% morbidity of lung cancer.[@b2-ott-9-2683],[@b20-ott-9-2683]--[@b22-ott-9-2683] In recent years, small (≤2 cm) invasive lung adenocarcinoma could be easily detected by using a wide application of low-dose spiral computed tomography screening.[@b3-ott-9-2683],[@b23-ott-9-2683] However, invasive adenocarcinoma shows poorer prognosis than adenocarcinoma in situ, and minimally invasive adenocarcinoma among small lung adenocarcinoma. Meanwhile, different types of invasive adenocarcinoma show different outcomes according to the IASLC/ATS/ERS's international multidisciplinary classification of lung adenocarcinoma,[@b5-ott-9-2683],[@b24-ott-9-2683]--[@b26-ott-9-2683] and the different gene phenotype in individuals leads to a significant difference in outcomes. Therefore, it is important to detect and identify new molecular biomarkers for an accurate prediction of prognosis.[@b27-ott-9-2683] In this study, patients with small invasive lung adenocarcinoma were enrolled and the association between YBX1 expression and prognosis was retrospectively investigated to evaluate the expression of YBX1 in different human lung adenocarcinoma cell lines by comparison with normal lung fibroblast cell line.

YBX1, a multifunctional protein, was reported to be excessively activated in many malignant tumors and to be involved in cell proliferation, cell cycle, and drug resistance.[@b28-ott-9-2683] The CSD domain of YBX1 could interact with inverted CCAAT boxes (Y-boxes) in promoter regions of some oncogenes, such as multidrug resistance 1, PCNA, and cell division cycle 6, and thereby regulate the transcription of these genes. Shibahara et al[@b29-ott-9-2683] reported that the positive expression of YBX1 was associated with lymph node metastasis and poor prognosis, and it may be a marker of progression in lung squamous carcinoma. To our knowledge, it might the first time the expression of YBXI in small invasive lung adenocarcinoma has been studied. In this study, the level of YBX1 was precisely assessed in primary lesions by comparison with normal adjacent tissue using ROC curve analyses. This procedure may be difficult, but it is more accurate than visual observation. Previous research showed that YBX1 was expressed in cytoplasm, but it would shift into the nuclear irradiation with ultraviolet treatment or treatment with anticancer drugs.[@b30-ott-9-2683],[@b31-ott-9-2683] Consistent with this, our study also detected that YBX1 protein appeared primarily in cytoplasm. We found that 31 (41.3%) patients with small invasive lung adenocarcinoma had high YBX1 expression mainly distributed in cytoplasm, but not in nucleus (\<3%). Nevertheless, Gu et al[@b32-ott-9-2683] reported the higher proportion of YBX1 expression appeared in the early stage of lung cancer. The inconsistent results may be caused by the fact that our study focused on invasive adenocarcinoma and especially those with the diameter ≤2 cm in the enrolled patients. Furthermore, human lung adenocarcinoma cells such as A549, H322, Hcc827, and H1299 exhibited more expression of YBX1 than HLF cells by Western blot analysis, confirming the high expression of YBX1 in lung adenocarcinoma again.

Among all 75 patients with small invasive lung adenocarcinoma after complete surgical resection, high expression of YBX1 is significantly associated with pathological grade (*P*=0.026) and differentiation (*P*=0.009) but not with other clinical pathologic factors. More interestingly, the patients with the higher IASLC/ATS/ERS pathological risk grade or poorer differentiation tend to have more YBX1 expression. These findings are consistent with the report by Dahl et al[@b33-ott-9-2683] that YBX1 expression showed a significant relationship with the differentiation in breast carcinoma (*P*=0.011). In the high pathological risk group of patients with micropapillary and solid predominant lung adenocarcinoma, the proportion of high YBX1 expression was up to 69.2%. But in the low pathological risk group of patients with lepidic predominant of adenocarcinoma, the proportion of high YBX1 expression was only 22.7%. Generally, the pathological grade and differentiation were frequently used as risk factors of prognosis in different tumors.[@b34-ott-9-2683],[@b35-ott-9-2683] Our study found higher pathological grade risk (*P*=0.014), poorer differentiation (*P*=0.014), lymph node metastasis (*P*=0.037), elevated TNM staging (*P*=0.042), and high YBX1 expression (*P*=0.039) affected the OS in the enrolled patients by log-rank test. In the further multivariate analysis, elevated TNM staging (OR =3.323; 95% CI, 1.059--10.432; *P*=0.040) and high YBX1 expression (OR =2.737; 95% CI, 1.058--7.082; *P*=0.038) were shown as independent risk factors of OS, while IASLC/ATS/ERS pathological grade risk exerted its prognostic values only in univariate analysis but not in multivariate analysis. By assessing the YBX1 expression, it would be possible to select high-risk patients who might benefit from early intervention at the early stage of lung adenocarcinoma. However, it was a pity to find that YBX1 expression (OR =1.696; 95% CI, 0.616--4.673; *P*=0.307) was not associated with the patients' DFS in Cox proportional hazards model, which might be caused by the limitation of the number of patients enrolled, and further research is needed for more accurate individualized treatment.

Conclusion
==========

In conclusion, the expression of YBX1 plays an important role in predicting prognosis, but there was no recurrence in patients with small invasive lung adenocarcinoma after complete resection. However, the limitation of this study was a small sample size, which can result in bias. Therefore, a larger sample size and randomized, and controlled clinical trials are required for further verification.
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![ROC curve to analyze the diacritic expression of YBX1.\
**Note:** The AUC was 0.734 with a specificity of 74.7% and sensitivity of 66.7%.\
**Abbreviations:** AUC, area under the ROC curve; CI, confidence interval; ROC, receiver operating characteristic.](ott-9-2683Fig1){#f1-ott-9-2683}

![Expression of YBX1 in different pathological grade risk group.\
**Notes:** The grade risk groups are in accordance with IASLC/ATS/ERS's international multidisciplinary classification of lung adenocarcinoma.[@b5-ott-9-2683] Lepidic, acinar, and micropapillary predominant growth pattern as the typical representativeness had shown high and low expression of YBX1, respectively, by immunohistochemistry (magnification ×400).\
**Abbreviations:** IASLC/ATS/ERS, International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society; Aci, acinar predominant adenocarcinoma; Lep, lepidic predominant adenocarcinoma; Mp, micropapillary predominant adenocarcinoma.](ott-9-2683Fig2){#f2-ott-9-2683}

![Analysis of total protein extracted from human lung adenocarcinoma cell lines and normal human embryonic lung fibroblasts cell line by Western blot.\
**Notes:** Histogram was used as the quantification of YBX1 expression in different cell lines. Expression of YBX1 was calculated relative to the GAPDH expression. Data were repeated three times and are presented as mean ± SD (\**P*\<0.05, \*\**P*\<0.01).\
**Abbreviations:** GADPH, glyceraldehyde-3-phosphate dehydrogenase; SD, standard deviation.](ott-9-2683Fig3){#f3-ott-9-2683}

![Kaplan--Meier survival curves for overall survival in 75 patients with small invasive lung adenocarcinoma after complete resection.\
**Notes:** (**A**) and (**B**) Patients with higher pathological grade risk (*P*=0.014) or elevated TNM staging (*P*=0.042) had a shorter overall survival. (**C**) High expression of YBX1 was associated with worse overall survival (*P*=0.039) in lung adenocarcinoma.\
**Abbreviation:** TNM, tumor, node, metastases.](ott-9-2683Fig4){#f4-ott-9-2683}

![Kaplan--Meier survival curves for disease free survival in 75 patients with small invasive lung adenocarcinoma after complete resection.\
**Notes:** (**A**) and (**B**) Patients with higher pathological grade risk (*P*=0.035) or poorer differentiation (*P*\<0.001) had a shorter disease free survival. (**C**) High expression of YBX1 was associated with worse disease free survival (*P*=0.024) compared with low expression.](ott-9-2683Fig5){#f5-ott-9-2683}

###### 

Clinicopathologic characteristics in 75 patients with completely resected small (≤2 cm) invasive lung adenocarcinoma

  Characteristics                    Number (%)
  ---------------------------------- ------------
  Total                              75 (100)
  Sex                                
   Male                              37 (49.3)
   Female                            38 (50.7)
  Age                                
   ≤64 years                         39 (52.0)
   \>64 years                        36 (48.0)
  Pathological grade risk            
   Low-grade risk (Lep)              22 (29.3)
   Middle-grade risk (Pap + Aci)     40 (53.3)
   High-grade risk (Mp + Sol + Mc)   13 (17.3)
  Differentiation                    
   Well                              39 (52.0)
   Moderate                          31 (41.3)
   Poor                              5 (6.7)
  Pleural invasion                   
   Absent                            67 (89.3)
   Present                           8 (10.7)
  Lymph node metastasis              
   Absent                            65 (86.7)
   Present                           10 (13.3)
  T size                             
   ≤1 cm                             35 (46.7)
   \>1 cm and ≤2 cm                  40 (53.3)
  TNM stage                          
   Ia                                58 (77.3)
   Ib                                7 (9.3)
   IIa                               10 (13.3)
  Surgical procedures                
   Lobectomy                         62 (87.2)
   Wedge resection                   13 (17.3)
  YBX1 expression                    
   High expression                   31 (41.3)
   Low expression                    44 (58.7)

**Abbreviations:** Aci, acinar predominant adenocarcinoma; Lep, lepidic predominant adenocarcinoma; Mc, mucinous predominant adenocarcinoma; Mp, micropapillary predominant adenocarcinoma; Pap, papillary predominant adenocarcinoma; Sol, solid predominant adenocarcinoma; TNM, tumor, node, metastases.

###### 

Relations between the expression of YBX1 and clinicopathologic characteristics in invasive lung adenocarcinoma

  Characteristics                    YBX1 expression   *P*-value   
  ---------------------------------- ----------------- ----------- -----------
  Total                              31 (41.3)         44          
  Sex                                                              0.740
   Male                              16 (43.2)         21          
   Female                            15 (39.5)         23          
  Age                                                              0.143
   ≤64 years                         13 (33.3)         26          
   \>64 years                        18 (50.0)         18          
  Pathological grade risk                                          **0.026**
   Low-grade risk (Lep)              5 (22.7)          17          
   Middle-grade risk (Pap + Aci)     17 (42.5)         23          
   High-grade risk (Mp + Sol + Mc)   9 (69.2)          4           
  Differentiation                                                  **0.009**
   Well                              10 (25.6)         29          
   Moderate                          17 (54.8)         14          
   Poor                              4 (80)            1           
  Pleural invasion                                                 0.198
   Absent                            26 (38.8)         41          
   Present                           5 (62.5)          3           
  Lymph node metastasis                                            0.732
   Absent                            26 (40.0)         39          
   Present                           5 (50.0)          5           
  T size                                                           
   ≤1 cm                             10 (28.6)         25          
   \>1 cm and ≤2 cm                  21 (52.5)         19          
  TNM stage                                                        0.520
   Ia                                22 (37.9)         36          
   Ib                                4 (57.1)          3           
   IIa                               5 (50.0)          5           

**Notes:** Statistical significance was evaluated using the chi-square test. Differences were considered to be statistically significant for *P*-values of \<0.05 which are shown in bold.

**Abbreviations:** Aci, acinar predominant adenocarcinoma; Lep, lepidic predominant adenocarcinoma; Mc, mucinous predominant adenocarcinoma; Mp, micropapillary predominant adenocarcinoma; Pap, papillary predominant adenocarcinoma; Sol, solid predominant adenocarcinoma; TNM, tumor, node, metastases.

###### 

Univariate analysis of 5-year OS and disease-free survival on different clinicopathological factors using Kaplan--Meier method

  Risk factor                        Kaplan--Meier method                      
  ---------------------------------- ---------------------- ----------- ------ -------------
  Sex                                                       0.183              0.402
   Male                              58.0                               63.8   
   Female                            76.6                               74.4   
  Age                                                       0.463              0.747
   ≤64 years                         71.2                               71.1   
   \>64 years                        62.9                               67.8   
  Pathological grade risk                                   **0.014**          **0.035**
   Low-grade risk (Lep)              86.1                               82.9   
   Middle-grade risk (Pap + Aci)     66.7                               68.8   
   High-grade risk (Mp + Sol + Mc)   30.0                               43.5   
  Differentiation                                           **0.014**          \<**0.001**
   Well                              84.7                               89.0   
   Moderate                          53.9                               52.9   
   Poor                              32.3                               30.0   
  Pleural invasion                                          0.080              **0.020**
   Absent                            69.4                               75.2   
   Present                           50.0                               33.3   
  Lymph node metastasis                                     **0.037**          **0.036**
   Absent                            70.3                               73.3   
   Present                           58.3                               50.0   
  T size                                                    0.879              0.207
   ≤1 cm                             70.0                               76.3   
   \>1 cm and ≤2 cm                  60.1                               64.2   
  TNM stage                                                 **0.042**          **0.044**
   I                                 70.3                               73.3   
   II                                56.0                               50.0   
  Surgical procedures                                       0.475              0.133
   Lobectomy                         64.0                               65.9   
   Wedge resection                   83.1                               88.9   
  YBX1 expression                                           **0.039**          **0.024**
   High expression                   79.0                               79.4   
   Low expression                    52.3                               54.3   

**Notes:** Statistical significance was evaluated using the log-rank test. Differences were considered to be statistically significant for *P*-values of \<0.05 which are shown in bold.

**Abbreviations:** Aci, acinar predominant adenocarcinoma; Lep, lepidic predominant adenocarcinoma; Mc, mucinous predominant adenocarcinoma; Mp, micropapillary predominant adenocarcinoma; Pap, papillary predominant adenocarcinoma; Sol, solid predominant adenocarcinoma; TNM, tumor, node, metastases; 5-FDS, 5-year disease free survival; 5-OS, 5-year overall survival.

###### 

Multivariate analysis of overall survival using Cox regression

  Factors                            OR      95% CI          *P*-value
  ---------------------------------- ------- --------------- -----------
  Pathological grade risk                                    
   Low-grade risk (Lep)              0.558   0.076--4.122    0.568
   Middle-grade risk (Pap + Aci)     1.352   0.236--7.754    0.735
   High-grade risk (Mp + Sol + Mc)   1                       
  Differentiation                                            
   Well                              0.190   0.036--1.004    0.051
   Moderate                          0.556   0.192--1.611    0.279
   Poor                              1                       
  Lymph node metastasis                                      
   Absent                            0.388   0.011--13.570   0.601
   Present                           1                       
  TNM stage                                                  
   II                                3.323   1.059--10.432   **0.040**
   I                                 1                       
  YBX1 expression                                            
   High expression                   2.737   1.058--7.082    **0.038**
   Low expression                    1                       

**Notes:** Statistical significance was evaluated using the Cox regression test. Differences were considered to be statistically significant for *P*-values \<0.05 which are shown in bold.

**Abbreviations:** Aci, acinar predominant adenocarcinoma; CI, confidence interval; Lep, lepidic predominant adenocarcinoma; Mc, mucinous predominant adenocarcinoma; Mp, micropapillary predominant adenocarcinoma; OR, odds ratio; Pap, papillary predominant adenocarcinoma; Sol, solid predominant adenocarcinoma; TNM, tumor, node, metastases.

###### 

Multivariate analysis of disease-free survival using Cox regression

  Factors                            OR      95% CI          *P*-value
  ---------------------------------- ------- --------------- -----------
  Pathological grade risk                                    
   Low-grade risk (Lep)              0.583   0.113--3.024    0.521
   Middle-grade risk (Pap + Aci)     1.262   0.375--4.265    0.706
   High-grade risk (Mp + Sol + Mc)   1                       
  Differentiation                                            
   Well                              0.123   0.028--0.553    **0.006**
   Moderate                          0.668   0.189--2.362    0.531
   Poor                              1                       
  Pleural invasion                                           
   Absent                            1                       
   Present                           2.401   0.808--7.128    0.115
  Lymph node metastasis                                      
   Absent                            0.401   0.016--10.129   0.579
   Present                           1                       
  TNM stage                                                  
   II                                2.383   0.828--6.862    0.107
   I                                 1                       
  YBX1 expression                                            
   High expression                   1.696   0.616--4.673    0.307
   Low expression                    1                       

**Note:** Statistical significance was evaluated using the Cox regression test. Differences were considered to be statistically significant for *P*-values \<0.05 and marked in bold.

**Abbreviations:** Aci, acinar predominant adenocarcinoma; CI, confidence interval; Lep, lepidic predominant adenocarcinoma; Mc, mucinous predominant adenocarcinoma; Mp, micropapillary predominant adenocarcinoma; OR, odds ratio; Pap, papillary predominant adenocarcinoma; Sol, solid predominant adenocarcinoma; TNM, tumor, node, metastases.
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